Reproductive and Urogenital Pharmacology
Abstract
Reproductive and urogenital pharmacology encompasses the pharmacological basis of therapies that target reproductive endocrinology, fertility modulation, sexual function, and lower urinary tract disorders. The field integrates hormonal regulation with drug discovery, addressing both male and female reproductive health. Hormonal contraceptives remain a cornerstone of family planning, involving estrogen-progestin combinations and progestin-only formulations, each with distinct mechanisms and risk-benefit profiles. Fertility treatments, including ovulation induction with clomiphene and gonadotropins, have advanced assisted reproductive technologies but pose complications such as ovarian hyperstimulation syndrome (OHSS). Androgen modulators such as testosterone therapy, anti-androgens, and 5α-reductase inhibitors play critical roles in conditions like hypogonadism, prostate cancer, and polycystic ovary syndrome (PCOS). Hormone replacement therapy (HRT) during menopause continues to raise debate over cardiovascular risks and cancer incidence, necessitating individualized approaches. Pharmacological interventions for benign prostatic hyperplasia (BPH), erectile dysfunction, and urinary incontinence highlight the relevance of α-blockers, phosphodiesterase-5 inhibitors, β3 agonists, and intravesical botulinum toxin. Finally, drug safety in pregnancy and lactation remains paramount, as teratogenic risks and FDA classifications guide therapeutic decision-making. This chapter provides…
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.